Wockhardt Shares Gain 16% After US FDA Clears Novel Antibiotic Zaynich

Wockhardt's Shares Surge Over 10% as FDA Approves Novel Antibiotic Zaynich

Shares of pharma major Wockhardt surged more than 10% on Monday after the company secured US Food and Drug Administration (FDA) approval for its novel antibiotic Zaynich, marking a significant milestone in its decades-long research effort.

The stock had surged as much as 16.21% at the opening trade following the FDA approval announcement before paring some gains. It was still up 12.2% at Rs 2,279 on the NSE at 9:42 am on Monday. Zaynich is designed to treat complicated urinary tract infections (cUTI), including pyelonephritis, and targets infections caused by drug-resistant Gram-negative bacteria.

The approval comes at a time when antimicrobial resistance is emerging as a growing global health challenge, limiting treatment options for physicians. For Wockhardt, the approval marks the culmination of years of investment in building a proprietary antibiotic research pipeline.

Read also: Expert Portfolio Manager Raja Venkatraman Names Top Investment Picks for June 4

With regulatory clearances now secured in both the US and India, the company has crossed a significant scientific hurdle that only a handful of Indian pharmaceutical firms have achieved. The focus now shifts to commercial execution. Having demonstrated its ability to discover and develop a globally relevant antibiotic, Wockhardt must prove that innovation can translate into sustainable revenue growth and profitability.

Wockhardt's antibiotic programme addresses a critical gap in the market left by large global pharmaceutical companies that have scaled back investments in antibiotic research. The company is focused on combating Gram-negative resistant infections, one of the most difficult and rapidly evolving threats in infectious diseases.

According to company estimates, around two million patients globally suffer from Gram-negative resistant infections. Wockhardt pegs the total addressable market for Zaynich at nearly $9 billion across the US, Europe, and India.

Read also: MarketSmith India's 4 June Stock Recommendations

In India alone, the company estimates that nearly 1.1 million resistant infection cases could be addressed by the drug, translating into a market opportunity of around Rs 17,000 crore. Across the US and Europe, Wockhardt estimates the addressable opportunity at roughly $7 billion.